Central Nervous System News and Research

RSS

Spinifex secures AU$6.25 million in expanded Series B funding

Spinifex Pharmaceuticals, an Australian pain drug development company, today announced it has secured a further AU$6.25 million of venture capital investment from GBS Venture Partners Limited, Brandon Capital Partners Pty Limited, Uniseed Management Pty Limited and UniQuest Pty Limited to fund the development of its pain management drug, EMA401.

23 Aug 2011

New report on the immunomodulators market outlook to 2016

TNF inhibitors indicated for the treatment of rheumatoid arthritis, psoriasis and inflammatory bowel disease formed the largest share of the market, according to a new report available on companiesandmarkets.com. The top three products: Remicade, Humira and Enbrel accounted for 40.1% of the market in 2010.

23 Aug 2011

Researchers to generate new knowledge about brain's complex communication system

Researchers at the Faculty of Pharmaceutical Sciences at the University of Copenhagen have collaborated with the company NeuroSearch to generate new knowledge about an important part of the brain's complex communication system.

20 Aug 2011

DiaGenic reports operating revenue of NOK 1,151 thousand for second quarter 2011

DiaGenic: Important milestones achieved. DiaGenic's collaboration with Pfizer is the first collaboration between a diagnostics company and the market leader for Alzheimer's therapeutics that aims to identify blood based diagnostic tools that can detect early Alzheimer's disease, before the disease is clinically overt, or accessible to other either more invasive and costly or less precise diagnostic exploration.

19 Aug 2011

LYSOGENE launches the first gene therapy clinical trials in Sanfilippo disease

LYSOGENE announces the authorization by AFSSAPS (the French Agency for the Safety of Health Products) and by the Ethical Review Board of SAF-301, its leading intra-cerebral gene therapy phase I/II clinical trial aiming at treating Sanfilippo Type A Syndrome.

16 Aug 2011

Second annual CNS Summit to shape the future of drug development

Segal Institute for Clinical Research, a consortium of CNS and women's health research sites, is preparing to again be actively involved in CNS Summit this coming fall.

12 Aug 2011

Endothelial progenitor cells may repair leaky blood-brain barrier

University of South Florida Department of Neurosurgery and Brain Repair faculty members have received a $2.6 million grant from the National Institutes of Health to investigate the potential for cells derived from human bone marrow to benefit post-stroke patients by repairing the blood-brain barrier.

12 Aug 2011

China Pharma second quarter revenue increases 18% to $19.6 million

China Pharma Holdings, Inc., a specialty pharmaceuticals company in China, today announced financial results for the quarter ended June 30, 2011.

11 Aug 2011

FUS Foundation awards $112,002 grant to Harvard brain researcher

The Focused Ultrasound Surgery Foundation has announced its latest Research Award recipient is Nathan McDannold, Ph.D. The $112,002 award will support McDannold's efforts to increase the regions in the brain that can be safely targeted by MR-guided focused ultrasound, an innovative, noninvasive medical technology being championed by the Foundation.

11 Aug 2011

57 genes associated with multiple sclerosis

An international research team has found nearly 30 genetic risk factors that predispose to developing multiple sclerosis. It brings to more than 50 the total number of genetic clues to the disease. The research, published in Nature, will help identify risk factors and perhaps future treatments or even a cure, hopes the MS Society.

11 Aug 2011

Scientist determines how nyctalopin gene makes night vision possible

A scientist from the Florida campus of The Scripps Research Institute has determined how a particular gene makes night vision possible. The study, which was published in the August 10, 2011 edition of The Journal of Neuroscience, focuses on a gene called nyctalopin. Mutations in the gene result in inherited "night blindness," a loss of vision in low-light environments.

10 Aug 2011

EPO issues European patent for Rexahn's neurotherapeutic compositions

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office (EPO) has granted European patent No. EP1212055 entitled "Neurotherapeutic compositions comprising a beta-lactam compound."

9 Aug 2011

NIH awards Jefferson $4.8M grant to study vaccine to clear rabies virus from central nervous system

Thomas Jefferson University received a National Institutes of Health (NIH) $4.8 million grant to test a new rabies vaccine with the potential to cure the virus infection, even after it has made its way into a person's central nervous system (CNS). Today, if an unvaccinated person is infected with rabies and it spreads to the brain, there is little chance for survival.

8 Aug 2011

Simcyp extends application in areas of PD modelling and drug distribution within CNS

Simcyp Limited is pleased to announce significant additions to its flagship simulator in line with priorities established by the Simcyp Consortium of global pharmaceutical companies.

6 Aug 2011

Scientists convert human skin cells into forebrain neurons

Columbia University Medical Center researchers have for the first time directly converted human skin cells into functional forebrain neurons, without the need for stem cells of any kind.

5 Aug 2011

Researchers identify genes that play a key role in pain perception

By working with individuals suffering from a severe disorder that causes sensory neurons to degenerate, researchers at the University of Montreal Hospital and CHU Sainte-Justine Hospital have discovered how a specific genetic mutation causes their patients' condition, which in turn has revealed more information about the mechanisms in our bodies which enable us to sense pain.

5 Aug 2011

Insight into how brain organizes during development

Scientists at the Allen Institute for Brain Science have taken an important step in identifying how the brain organizes itself during development. The findings, published in the Journal of Comparative Neurology today, describe - in more detail than ever before - the consequences of the loss of a key molecule involved in establishing proper brain architecture during brain development.

3 Aug 2011

Vanda, Biotoscana Farma partner to commercialize Fanapt in Argentina

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced its exclusive license agreement with Argentina-based Biotoscana Farma S.A., a wholly owned affiliate of Biotoscana International, based in Bogota, Colombia, for the commercialization of Fanapt ™ in Argentina.

1 Aug 2011

Artificial nanoparticles have direct effect on heart rate and rhythm

Artificial nanoparticles are becoming increasingly pervasive in modern life. However, their influence on our health and the mechanisms by which they affect the human body remain largely shrouded in mystery.

1 Aug 2011

Therapeutic hypothermia might not be effective for children after heart attack

Intravenous delivery of cold fluids to reduce body temperature quickly after a heart attack and improve neurologic outcomes may not be as effective in children as it is in adults, according to a study reported in Therapeutic Hypothermia and Temperature Management, a peer-reviewed journal published by Mary Ann Liebert, Inc.

30 Jul 2011